Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.

Max O MeneveauGina R PetroniElise P SalernoKevin T LynchMark SmolkinElizabeth WoodsonKimberly A Chianese-BullockWalter C OlsonDonna DeaconJames W PattersonWilliam W GroshCraig L Slingluff

Published in: Journal for immunotherapy of cancer (2022)

These data provide proof of principle for immunogenicity in humans of transdermal immunization using peptides in DMSO. Further study is warranted into the pharmacokinetics and immunobiology of TLR agonists as vaccine adjuvants during transcutaneous application. Overall survival is high, supporting further investigation of this immunization approach.

Keyphrases

toll like receptor
inflammatory response
immune response
electronic health record
nuclear factor
machine learning
deep learning
basal cell carcinoma